Transfer factor therapy in multiple sclerosis: a three-year prospective double-blind clinical trial.
One hundred five patients with MS were divided into three groups matched for age, sex, and disability, and treated with either placebo, transfer factor prepared from leukocytes of random donors, or transfer factor from leukocytes of family members living with the patients. There were no differences in the three treatment groups for changes in disability, activities of daily living, or evoked potentials. Eighteen months of transfer factor therapy had no effect on gamma-interferon production or natural killer cell activities.
D000203:Activities of Daily Living; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005071:Evoked Potentials; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D007694:Killer Cells, Natural / Q000276:immunology; D007962:Leukocytes / Q000378:metabolism; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D014165:Transfer Factor / Q000627:therapeutic use*
D014165:Transfer Factor; D007371:Interferon-gamma